Detalhe da pesquisa
1.
Randomized double-blind, placebo-controlled multicenter phase III study of prevention of irinotecan-induced diarrhea by a probiotic mixture containing Bifidobacterium BB-12®Lactobacillus rhamnosus LGG® in colorectal cancer patients.
Front Oncol;
13: 1168654, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37601667
2.
Feasibility of two dose-dense FEC regimens with growth factor support for adjuvant therapy in patients with early breast cancer: results from a randomised study of the Central European Cooperative Oncology Group (CECOG).
Breast Cancer Res Treat;
112(3): 557-63, 2008 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18189160
3.
Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial.
J Clin Oncol;
23(7): 1401-8, 2005 Mar 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-15735116
4.
Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial.
Lung Cancer;
52(2): 155-63, 2006 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16569462
5.
Tumour topoisomerase II alpha protein expression and outcome after adjuvant dose-dense anthracycline-based chemotherapy.
Pathol Oncol Res;
18(1): 61-8, 2012 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21681601
6.
Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study.
J Clin Oncol;
27(19): 3097-103, 2009 Jul 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19451434